Floatz logo

Dacomitinib

Carcinoma, Large Cell

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Carcinoma, Large Cell cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Vinorelbine
AIO-Studien-gGmbH
Phase 3BB
Gefetinib
National Cancer Institute (NCI)
Phase 3BB

View all 34 →

Same molecule, other indications

Dacomitinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
brain neoplasmDormant
B
Indicative ·
57 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →